Hagsund, Tora
Olsson, Sven-Erik
Smith, J. Gustav
Madsen Hardig, Bjarne
Wagner, Henrik
Funding for this research was provided by:
Swedish Heart-Lung Foundation (2016-0134 2016-0315)
European Research Council (ERC-STG 2015-67242)
Crafoord Foundation, Skåne University Hospital, the Scania county, governmental funding of clinical research within the Swedish National Health Service (NA)
Governmental funding of clinical research within the Swedish National Health Service (NA)
Knut and Alice Wallenberg foundation to the Wallenberg Center for Molecular Medicine in Lund (NA)
Swedish Research Council (Linnaeus grant Dnr 349-2006-237, Strategic Research Area Exodiab Dnr 2009-103)
Swedish Foundation for Strategic Research (Dnr IRC15-0067)
Article History
Received: 2 May 2019
Accepted: 18 March 2020
First Online: 9 April 2020
Ethics approval and consent to participate
: The study was performed by the first author, within the medical education and since the study was a quality work regarding given treatment recommended in national Swedish and European guidelines, ethical approval is not needed [CitationRef removed–CitationRef removed]. All patients gave written and verbal informed consent to participate in the Riks-HIA and SCAAR registries at the time at their admission at the coronary unit or at the coronary catheterization laboratory. Hence Application for ethical approval from the local Swedish Ethical Review Authority at Lund University, was thereby waived (Dnr 2017/885).
: All patients have given written and verbal informed consent to participate in the Riks-HIA and SCAAR registries, which includes the approval for analysis of the data and publication in scientific journals.
: The authors declare that they have no competing interests.